India, Aug. 24 -- InnoCare Pharma(INCPF), a biopharmaceutical company focused on cancer and autoimmune diseases, reported strong financial results for the first half of 2026, sustained profitability and multiple clinical and regulatory milestones across its pipeline.
Company Profile
China-based InnoCare is focused on developing innovative therapies for cancer and autoimmune diseases.
Its portfolio includes BTK inhibitor orelabrutinib, BCL2 inhibitor mesutoclax, two TYK2 inhibitors, and multiple antibody-drug conjugate (ADC) and molecular glue programs.
H1 2026 Financial Highlights
Revenue increased 55.5% year over year to RMB 1.1 billion from RMB 731.4 million, driven by commercial growth and global business development collaborations....